CAMP4 FY2025 net loss $80.4M; cash runway into 2028, GSK deal, SYNGAP1 progress

Camp4 Therapeutics Corp

Net loss of $80.4M in FY2025 vs $51.8M in FY2024, driven by $29.8M non-cash loss on derivative tranche liability.
Cash and equivalents $109.5M (Dec 31, 2025), up from $64.0M; cash runway extended into 2028.
GSK collaboration: $17.5M upfront, up to $440M in milestones plus tiered royalties for ASO candidates in neurodegenerative and kidney diseases.
GLP tox studies for CMP-002 ongoing; global Phase 1/2 trial in SYNGAP1 patients expected as early as H2 2026.
Paused development of CMP-001 and exploring partnership opportunities for that program.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Camp4 Therapeutics Corp reported the year ended December 31, 2025 results: net income $80.4 million.

Period: the year ended December 31, 2025
Net income: $80.4 million
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2025, was $80.4 million compared to $51.8 million for the year ended December 31, 2024.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Camp4 Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001736730-26-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.